Multiple groups have now shown that Tpex cells are the target of anti‐PD1 immunotherapy and that enhanced anti‐cancer immunity with anti‐PD1 immunotherapy requires Tcf7/TCF1 [92, 93]. This evidence concerns the gene TCF7 and cancer.